Aljian Capital Management’s AbbVie ABBV Stock Holding History

Aljian Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.52M	Buy	7,000 +914	+15%	+$203K	0.31%	46
2025 Q4	$1.39M	Sell	6,086 -224	-4%	-$51K	0.28%	47
2025 Q3	$1.46M	Sell	6,310 -16	-0.3%	-$3.26K	0.29%	47
2025 Q2	$1.17M	Sell	6,326 -377	-6%	-$70.1K	0.26%	52
2025 Q1	$1.4M	Sell	6,703 -18	-0.3%	-$3.5K	0.33%	40
2024 Q4	$1.19M	Sell	6,721 -7	-0.1%	-$1.29K	0.26%	42
2024 Q3	$1.33M	Buy	+6,728	New	+$1.26M	0.31%	40
2019 Q3	–	Sell	-2,788	Closed	-$203K	–	49
2019 Q2	$203K	Sell	2,788 -325	-10%	-$25.5K	0.17%	53
2019 Q1	$251K	Sell	3,113 -690	-18%	-$56.4K	0.21%	47
2018 Q4	$351K	Buy	+3,803	New	+$334K	0.35%	40

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aljian Capital Management's ABBV Position: Q1 2026 in Review

Aljian Capital Management increased its AbbVie (ABBV) stake by 15% in Q1 2026, buying an estimated $203K and bringing the position to 7,000 shares worth $1.52M. The position accounts for 0.31% of the portfolio, ranked #46.

Aljian Capital Management first reported a position in ABBV in Q4 2018 and has held it in 10 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Aljian Capital Management held 7,000 shares of AbbVie worth $1.52M as of Q1 2026.
Aljian Capital Management bought 914 AbbVie shares in Q1 2026, an estimated $203K.
AbbVie made up 0.31% of Aljian Capital Management's portfolio in Q1 2026, its #46 holding.
Aljian Capital Management first reported a position in AbbVie in Q4 2018 and has held it in 10 quarters since.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Aljian Capital Management's 13F filing for Q1 2026, filed 29 Apr 2026.